Table 2. Clinicopathological findings according to Plk3 expression and pT273 Caspase-8 levels.
| No. of patients | Plk3 WS ≤ 6 n (%) | PLK3 WS > 6 n (%) | p-value | No. of patients | Casp8 ≤ Med n (%) | Casp8 > Med n (%) | p-value | |
|---|---|---|---|---|---|---|---|---|
|
Age ≤ 58 years > 58 years |
48 46 |
23 (67.6) 11 (32.4) |
25 (41.6) 35 (58.4) |
0.015 | 49 46 |
26 (56.5) 20 (43.5) |
24 (48.0) 26 (56.0) |
0.46 |
|
Gender male female |
40 54 |
17 (50.0) 17 (50.0) |
23 (38.3) 37 (61.7) |
0.27 | 41 54 |
25 (55.5) 20 (43.5) |
16 (32.0) 34 (68.0) |
0.02 |
|
T-stage T1/2 T3/4 Tx |
67 26 |
20 (60.6) 13 (39.4) |
47 (78.3) 13 (21.6) |
0.07 | 67 27 1 |
26 (57.7) 18 (40.0) 1 (2.3) |
41 (82.0) 9 (18.0) |
0.014 |
|
N-stage N0 N1-3 Nx |
61 27 6 |
21 (61.8) 10 (29.4) 3 (8.8) |
40 (66.6) 17 (28.4) 3 (5.0) |
0.81 | 61 28 6 |
25 (55.5) 16 (35.5) 4 (8.0) |
36 (72.0) 12 (24.0) 2 (4.0) |
0.15 |
|
Grading G1/2 G3 |
76 18 |
26 (76.4) 8 (23.6) |
50 (83.3) 10 (16.7) |
0.42 | 77 18 |
37 (82.3) 8 (17.7) |
40 (80.0) 10 (20.0) |
0.78 |
|
Total dose (including boost) ≤ 50.4 Gy > 50.4 Gy |
56 38 |
19 (55.9) 15 (44.1) |
37 (61.7) 23 (38.3) |
0.664 | 57 38 |
30 (66.7) 15 (33.3) |
27 (54.0) 23 (46.0) |
0.294 |
|
HPV-16 load HPV-16 Med HPV-16 > Med |
31 49 |
20 (50.0) 20 (50.0) |
11 (28,9) 29 (71.1) |
0.033 | 36 44 |
24 (60.0) 16 (40.0) |
12 (30.0) 28 (70.0) |
0.006 |
|
p16INK4A p16 WS ≤ 6 p16 WS > 6 |
22 72 |
7 (20.5) 27 (79.5) |
15 (27.7) 45 (72.3) |
0.063 | 33 62 |
17 (37.8) 28 (62.2) |
6 (12.0) 44 (88.0) |
0.003 |
|
HIV-status positive negative |
17 76 |
9 (27.3) 24 (72.7) |
8 (13.3) 52 (86.7) |
0.09 | 17 77 |
10 (22.7) 34 (77.3) |
7 (14.0) 43 (86.0) |
0.27 |
|
Plk3 Plk3 WS ≤ 6 Plk3 WS > 6 |
34 60 |
30 (68.2) 14 (31.8) |
4 (8.0) 46 (92.0) |
< 0.001 | ||||
|
pT273 Casp8 Casp8 ≤ Med Casp8 > Med |
44 50 |
30 (88.2) 4 (11.8) |
14 (23.3) 46 (76.6) |
< 0.0001 |